extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
e274808f19
commit
e6ba1bb984
6 changed files with 48 additions and 8 deletions
|
|
@ -113,6 +113,12 @@ Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow onl
|
|||
|
||||
International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
|
||||
|
||||
Aon's 192K patient dataset shows medical costs grow only 2% for GLP-1 users after 12 months versus 6% for non-users, with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests the 'inflationary through 2035' projection may only hold for short-term payers who don't capture the post-12-month savings trajectory.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -66,6 +66,12 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180
|
|||
|
||||
Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
|
||||
|
||||
Aon's dataset adds cancer risk reduction to the multi-organ protection profile: ~50% lower ovarian cancer and 14% lower breast cancer in female users, plus associations with lower osteoporosis and rheumatoid arthritis. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests protection mechanisms may be stronger or more diverse in women.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -95,6 +95,12 @@ Aon data shows the 80%+ adherent cohort captures dramatically stronger cost redu
|
|||
|
||||
GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacology cannot overcome behavioral determinants: patients on GLP-1 alone show same weight regain as placebo without behavior change. This is direct evidence that the 'human constraints' factor (Amodei framework) limits pharmaceutical efficacy independent of drug quality.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
|
||||
|
||||
Aon data shows adherence is the binding variable for cost-effectiveness: the 80%+ adherent cohort shows 9 percentage point lower cost growth for diabetes and 7 points lower for weight loss versus 6 and 3 points for the full cohort. This means the 15% two-year persistence rate doesn't just undermine economics—it concentrates all the value in the small persistent minority.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -49,6 +49,12 @@ The Trump Administration deal establishes a $50/month out-of-pocket maximum for
|
|||
|
||||
Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
|
||||
|
||||
Aon's finding that cost-effectiveness requires 80%+ adherence to achieve maximum savings (9 vs 6 percentage point cost reduction for diabetes) means affordability-driven discontinuation doesn't just affect individual outcomes—it prevents the system-level cost savings that would justify broader coverage, creating a self-reinforcing access barrier.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -1,13 +1,13 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md",
|
||||
"filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
|
|
@ -19,14 +19,14 @@
|
|||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
|
||||
"glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:set_created:2026-03-18"
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-19",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:set_created:2026-03-19"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:missing_attribution_extractor"
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
"date": "2026-03-19"
|
||||
}
|
||||
|
|
@ -7,13 +7,17 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-19
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -64,3 +68,15 @@ flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health inves
|
|||
- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
|
||||
- Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men
|
||||
- Study released January 13, 2026
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs 6% for non-users
|
||||
- Diabetes indication at 30 months: medical cost growth 6 percentage points lower; 9 points lower with 80%+ adherence
|
||||
- Weight loss indication at 18 months: cost growth 3 points lower; 7 points lower with consistent use
|
||||
- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
|
||||
- Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men
|
||||
- Study released January 13, 2026
|
||||
- Also associated with lower rates of osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations, bariatric surgery, and certain pancreatic disorders
|
||||
|
|
|
|||
Loading…
Reference in a new issue